Abstrakt

Przypisy

• 1. Anderson J.L., May H.T., Horne B.D., Bair T.L., Hall N.L., Carlquist J.F.,Lappé D.L., Muhlestein J.B.: Relation of vitamin D deficiency to cardiovascularrisk factors, disease status, and incident events in a generalhealthcare population. Am. J. Cardiol., 2010; 106: 963-968
  Google Scholar
• 2. Aref S., Ibrahim L., Azmy E.: Prognostic impact of serum 25-hydroxivitaminD [25(OH)D] concentrations in patients with lymphoid malignancies.Hematology, 2013; 18: 20-25
  Google Scholar
• 3. Arlet J.B., Callens C., Hermine O., Darnige L., Macintyre E., PouchotJ., Capron L.: Chronic lymphocytic leukaemia responsive to vitamin Dadministration. Br. J. Haematol., 2012; 156: 148-149
  Google Scholar
• 4. Aue G., Nelson Lozier J., Tian X., Cullinane A.M., Soto S., Samsel L.,McCoy P., Wiestner A.: Inflammation, TNFα and endothelial dysfunctionlink lenalidomide to venous thrombosis in chronic lymphocyticleukemia. Am. J. Hematol., 2011; 86: 835-840
  Google Scholar
• 5. Bittenbring J.T., Neumann F., Altmann B., Achenbach M., ReichrathJ., Ziepert M., Geisel J., Regitz E., Held G., Pfreundschuh M.: Vitamin Ddeficiency impairs rituximab-mediated cellular cytotoxicity and outcomeof patients with diffuse large B-cell lymphoma treated with butnot without rituximab. J. Clin. Oncol., 2014; 32: 3242-3248
  Google Scholar
• 6. Chang E.T., Canchola A.J., Cockburn M., Lu Y., Wang S.S., Bernstein L.,Clarke C.A., Horn-Ross P.L.: Adulthood residential ultraviolet radiation,sun sensitivity, dietary vitamin D, and risk of lymphoid malignancies inthe California Teachers Study. Blood, 2011; 118: 1591-1599
  Google Scholar
• 7. Chiorazzi N.: Cell proliferation and death: forgotten features of chroniclymphocytic leukemia B cells. Best Pract. Res. Clin. Haematol., 2007;20: 399-413
  Google Scholar
• 8. Davies J.R., Chang Y.M., Snowden H., Chan M., Leake S., KarpaviciusB., Haynes S., Kukalizch K., Randerson-Moor J., Elliott F., Barth J., KanetskyP.A., Harland M., Bishop D.T., Barrett J.H., Newton-Bishop J.A.:The determinants of serum vitamin D levels in participants in a melanomacase-control study living in a temperate climate. Cancer CausesControl, 2011; 22: 1471-1482
  Google Scholar
• 9. Dawson-Hughes B., Heaney R.P., Holick M.F., Lips P., Meunier P.J.,Vieth R.: Estimates of optimal vitamin D status. Osteoporos. Int., 2005;16: 713-716
  Google Scholar
• 10. Dighiero G., Hamblin T.J.: Chronic lymphocytic leukaemia. Lancet,2008; 371: 1017-1029
  Google Scholar
• 11. Döhner H., Stilgenbauer S., Benner A., Leupolt E., Kröber A., BullingerL., Döhner K., Bentz M., Lichter P.: Genomic aberrations and survivalin chronic lymphocytic leukemia. N. Engl. J. Med., 2000; 343: 1910-1916
  Google Scholar
• 12. Drake M.T., Maurer M.J., Link B.K., Habermann T.M., Ansell S.M.,Micallef I.N., Kelly J.L., Macon W.R., Nowakowski G.S., Inwards D.J., JohnstonP.B., Singh R.J., Allmer C., Slager S.L., Weiner G.J., et al.: Vitamin Dinsufficiency and prognosis in non-Hodgkin’s lymphoma. J. Clin. Oncol.,2010; 28: 4191-4198
  Google Scholar
• 13. Dudenkov D.V., Yawn B.P., Oberhelman S.S., Fischer P.R., Singh R.J.,Cha S.S., Maxson J.A., Quigg S.M., Thacher T.D.: Changing incidence ofserum 25-hydroxyvitamin D values above 50 ng/mL: a 10-year population-basedstudy. Mayo Clin. Proc., 2015; 90: 577-586
  Google Scholar
• 14. Erber E., Maskarinec G., Lim U., Kolonel L.N.: Dietary vitamin D andrisk of non-Hodgkin lymphoma: the multiethnic cohort. Br. J. Nutr.,2010; 103: 581-584
  Google Scholar
• 15. Etten E., Mathieu C.: Immunoregulation by 1,25-dihydroxyvitaminD3: basic concepts. J. Steroid Biochem. Mol. Biol., 2005; 97: 93-101
  Google Scholar
• 16. Firkin F., Seymour J.F., Watson A.M., Grill V., Martin T.J.: Parathyroidhormone-related protein in hypercalcaemia associated with haematologicalmalignancy. Br. J. Haematol., 1996; 94: 486-492
  Google Scholar
• 17. Garland C.F., Kim J.J., Mohr S.B., Gorham E.D., Grant W.B., GiovannucciE.L., Baggerly L., Hofflich H., Ramsdell J.W., Zeng K., Heaney R.P.:Meta-analysis of all-cause mortality according to serum 25-hydroxyvitaminD. Am. J. Public Health, 2014; 104: e43-50
  Google Scholar
• 18. Ghia P., Circosta P., Scielzo C., Vallario A., Camporeale A., GranzieroL., Caligaris-Cappio F.: Differential effects on CLL cell survival exertedby different microenvironmental elements. Curr. Top. Microbiol. Immunol.,2005; 294: 135-145
  Google Scholar
• 19. Gilchrest B.A.: Sun exposure and vitamin D sufficiency. Am. J. Clin.Nutr., 2008; 88: 570S-577S
  Google Scholar
• 20. Giovannucci E., Liu Y., Rimm E.B., Hollis B.W., Fuchs C.S., StampferM.J., Willett W.C.: Prospective study of predictors of vitamin D statusand cancer incidence and mortality in men. J. Natl. Cancer Inst., 2006;98: 451-459
  Google Scholar
• 21. Gröber U., Spitz J., Reichrath J., Kisters K., Holick M.F.: Vitamin D:Update 2013: From rickets prophylaxis to general preventive healthcare.Dermatoendocrinol., 2013; 5: 331-347
  Google Scholar
• 22. Hallek M., Cheson B.D., Catovsky D., Caligaris-Cappio F., DighieroG., Döhner H., Hillmen P., Keating M.J., Montserrat E., Rai K.R., KippsT.J.: Guidelines for the diagnosis and treatment of chronic lymphocyticleukemia: a report from the International Workshop on Chronic LymphocyticLeukemia updating the National Cancer Institute-WorkingGroup 1996 guidelines. Blood, 2008; 111: 5446-5456
  Google Scholar
• 23. Hathcock J.N., Shao A., Vieth R., Heaney R.: Risk assessment forvitamin D. Am. J. Clin. Nutr., 2007; 85: 6-18
  Google Scholar
• 24. Haussler M.R., Whitfield G.K., Haussler C.A., Hsieh J.C., ThompsonP.D., Selznick S.H., Dominguez C.E., Jurutka P.W.: The nuclear vitaminD receptor: biological and molecular regulatory properties revealed. J.Bone Miner. Res., 1998; 13: 325-349
  Google Scholar
• 25. Hayes C.E., Hubler S.L., Moore J.R., Barta L.E., Praska C.E., NasholdF.E.: Vitamin D actions on CD4(+) T cells in autoimmune disease. Front.Immunol., 2015; 6: 100
  Google Scholar
• 26. Hemachandar R., Shanmugam L., Malepati B., Venugopal S.: Hypervitaminosis D: are we overprescribing VD? J. Family Med. Prim. Care,2014; 3: 464-466
  Google Scholar
• 27. Hewison M., Kantorovich V., Liker H.R., Van Herle A.J., Cohan P.,Zehnder D., Adams J.S.: Vitamin D-mediated hypercalcemia in lymphoma:evidence for hormone production by tumor-adjacent macrophages.J. Bone Miner. Res., 2003; 18: 579-582
  Google Scholar
• 28. Hickish T., Cunningham D., Colston K., Millar B.C., Sandle J., MackayA.G., Soukop M., Sloane J.: The effect of 1,25-dihydroxyvitamin D3 onlymphoma cell lines and expression of vitamin D receptor in lymphoma.Br. J. Cancer, 1993; 68: 668-672
  Google Scholar
• 29. Holick M.F.: Vitamin D: evolutionary, physiological and health perspectives.Curr. Drug Targets, 2011; 12: 4-18
  Google Scholar
• 30. Holick M.F., Binkley N.C., Bischoff-Ferrari H.A., Gordon C.M., HanleyD.A., Heaney R.P., Murad M.H., Weaver C.M.: Evaluation, treatment, andprevention of vitamin D deficiency: an Endocrine Society clinical practiceguideline. J. Clin. Endocrinol. Metab., 2011; 96: 1911-1930
  Google Scholar
• 31. Holick M.F., Chen T.C.: Vitamin D deficiency: a worldwide problemwith health consequences. Am. J. Clin. Nutr., 2008; 87: 1080S-1086S
  Google Scholar
• 32. Holick M.F., Siris E.S., Binkley N., Beard M.K., Khan A., Katzer J.T., PetruschkeR.A., Chen E., de Papp A.E.: Prevalence of vitamin D inadequacyamong postmenopausal North American women receiving osteoporosistherapy. J. Clin. Endocrinol. Metab., 2005; 90: 3215-3224
  Google Scholar
• 33. Hollis B.W.: Circulating 25-hydroxyvitamin D levels indicative ofvitamin D sufficiency: implications for establishing a new effective dietaryintake recommendation for vitamin D. J. Nutr., 2005; 135: 317-322
  Google Scholar
• 34. Hyppönen E., Berry D., Cortina-Borja M., Power C.: 25-HydroxyvitaminD and pre-clinical alterations in inflammatory and hemostaticmarkers: a cross sectional analysis in the 1958 British Birth Cohort.PLoS One, 2010; 5: e10801
  Google Scholar
• 35. Kaur P., Mishra S.K., Mithal A.: Vitamin D toxicity resulting fromoverzealous correction of vitamin D deficiency. Clin. Endocrinol., 2015.83: 327-331
  Google Scholar
• 36. Kebapcilar A.G., Kulaksizoglu M., Ipekci S.H., Korkmaz H., KebapcilarL., Akyurek F., Taner C.E., Gonen M.S.: Relationship between meanplatelet volume and low-grade systemic coagulation with vitamin Ddeficiency in primary ovarian insufficiency. Arch. Gynecol. Obstet.,2013; 288: 207-212
  Google Scholar
• 37. Keum N., Giovannucci E.: Vitamin D supplements and cancer incidenceand mortality: a meta-analysis. Br. J. Cancer, 2014; 111: 976-980
  Google Scholar
• 38. Koul P.A., Ahmad S.H., Ahmad F., Jan R.A., Shah S.U., Khan U.H.:Vitamin D toxicity in adults: a case series from an area with endemichypovitaminosis D. Oman Med. J., 2011; 26: 201-204
  Google Scholar
• 39. Koyama T., Shibakura M., Ohsawa M., Kamiyama R., Hirosawa S.:Anticoagulant effects of 1α,25-dihydroxyvitamin D3 on human myelogenousleukemia cells and monocytes. Blood, 1998; 92: 160-167
  Google Scholar
• 40. Łuczyńska A., Kaaks R., Rohrmann S., Becker S., Linseisen J., BuijsseB., Overvad K., Trichopoulou A., Valanou E., Barmpitsioti A., Masala G.,Agnoli C., Tumino R., Panico S., Bueno-de-Mesquita H.B., et al.: Plasma 25-hydroxyvitamin D concentration and lymphoma risk: results of theEuropean Prospective Investigation into Cancer and Nutrition. Am. J.Clin. Nutr., 2013; 98: 827-838
  Google Scholar
• 41. Marckmann P., Agerskov H., Thineshkumar S., Bladbjerg E.M., SidelmannJ.J., Jespersen J., Nybo M., Rasmussen L.M., Hansen D., ScholzeA.: Randomized controlled trial of cholecalciferol supplementation inchronic kidney disease patients with hypovitaminosis D. Nephrol. Dial.Transplant., 2012; 27: 3523-3531
  Google Scholar
• 42. Mathieu C., Adorini L.: The coming of age of 1,25-dihydroxyvitaminD(3) analogs as immunomodulatory agents. Trends Mol. Med.,2002; 8: 174-179
  Google Scholar
• 43. Mithal A., Wahl D.A., Bonjour J.P., Burckhardt P., Dawson-HughesB., Eisman J.A., El-Hajj Fuleihan G., Josse R.G., Lips P., Morales-Torres J.:Global vitamin D status and determinants of hypovitaminosis D. Osteoporos.Int., 2009; 20: 1807-1820
  Google Scholar
• 44. Molica S., Digiesi G., Antenucci A., Levato L., Mirabelli R., MolicaM., Gentile M., Giannarelli D., Sperduti I., Morabito F., Conti L.: VitaminD insufficiency predicts time to first treatment (TFT) in early chroniclymphocytic leukemia (CLL). Leuk. Res., 2012; 36: 443-447
  Google Scholar
• 45. O’Brien S., del Giglio A., Keating M.: Advances in the biology andtreatment of B-cell chronic lymphocytic leukemia. Blood, 1995; 85: 307-318
  Google Scholar
• 46. Ordóñez-Mena J.M., Schöttker B., Fedirko V., Jenab M., Olsen A.,Halkjær J., Kampman E., de Groot L., Jansen E., Bueno-de-Mesquita H.B.,Peeters P.H., Siganos G., Wilsgaard T., Perna L., Holleczek B., et al.: Prediagnosticvitamin D concentrations and cancer risks in older individuals:an analysis of cohorts participating in the CHANCES consortium.Eur. J. Epidemiol., 2016; 31: 311-323
  Google Scholar
• 47. Pandita K.K., Razdan S., Kudyar R.P., Beigh A., Kuchay S., Banday T.:‘Excess gooD can be Dangerous’. A case series of iatrogenic symptomatichypercalcemia due to hypervitaminosis D. Clin. Cases Miner. BoneMetab., 2012; 9: 118-120
  Google Scholar
• 48. Pepper C., Thomas A., Hoy T., Milligan D., Bentley P., Fegan C.: Thevitamin D3 analog EB1089 induces apoptosis via a p53-independentmechanism involving p38 MAP kinase activation and suppression ofERK activity in B-cell chronic lymphocytic leukemia cells in vitro. Blood,2003; 101: 2454-2460
  Google Scholar
• 49. Petrini M., Galbraith R.M., Werner P.A., Emerson D.L., Arnaud P.: Gc(vitamin D binding protein) binds to cytoplasm of all human lymphocytesand is expressed on B-cell membranes. Clin. Immunol. Immunopathol.,1984; 31: 282-295
  Google Scholar
• 50. Płudowski P., Karczmarewicz E., Bayer M., Carter G., ChlebnaSokółD., Czech-Kowalska J., Dębski R., Decsi T., Dobrzańska A., FranekE., Głuszko P., Grant W.B., Holick M.F., Yankovskaya L., KonstantynowiczJ., et al.: Practical guidelines for the supplementation of vitamin Dand the treatment of deficits in Central Europe — recommended VDintakes in the general population and groups at risk of VD deficiency.Endokrynol. Pol., 2013; 64: 319-327
  Google Scholar
• 51. Provvedini D.M., Tsoukas C.D., Deftos L.J., Manolagas S.C.: 1,25-dihydroxyvitaminD3 receptors in human leukocytes. Science, 1983; 221:1181-1183
  Google Scholar
• 52. Shanafelt T.D., Drake M.T., Maurer M.J., Allmer C., Rabe K.G., SlagerS.L., Weiner G.J., Call T.G., Link B.K., Zent C.S., Kay N.E., Hanson C.A., WitzigT.E., Cerhan J.R.: Vitamin D insufficiency and prognosis in chroniclymphocytic leukemia. Blood, 2011; 117: 1492-1498
  Google Scholar
• 53. Veldman C.M., Cantorna M.T., DeLuca H.F.: Expression of 1,25-dihydroxyvitaminD(3) receptor in the immune system. Arch. Biochem.Biophys., 2000; 374: 334-338
  Google Scholar
• 54. Wu-Wong J.R., Nakane M., Ma J., Ruan X., Kroeger P.E.: Effects of vitaminD analogs on gene expression profiling in human coronary arterysmooth muscle cells. Atherosclerosis, 2006; 186: 20-28
  Google Scholar
• 55. Yin L., Ordóñez-Mena J.M., Chen T., Schöttker B., Arndt V., BrennerH.: Circulating 25-hydroxyvitamin D serum concentration and totalcancer incidence and mortality: a systematic review and meta-analysis.Prev. Med., 2013; 57: 753-764
  Google Scholar
• 56. Zheng Y.T., Cui Q.Q., Hong Y.M., Yao W.G.: A meta-analysis of highdose, intermittent vitamin D supplementation among older adults.PLoS One, 2015; 10: e01158
  Google Scholar

Pełna treść artykułu